Similarly, we have previously shown that CSF biomarkers may be more sensitive to Aβ pathology compared to PET imaging.27 The fact that CSF tau measures did not differ between prodromal AD and AD dementia suggests that these biomarkers plateau at the prodromal stage of the disease. This evidence concerns the gene MAPT and Alzheimer disease.